Pilot Study Evaluating the Safety of a Combined Central Venous Catheter and Inferior Vena Cava Filter in Critically Ill Patients at High Risk of Pulmonary Embolism

Cadavid, Carlos A.; Gil, Bladimir; Restrepo, Alvaro; Álvarez, Sergio; Echeverry, Santiago; Angel, Luis F.; Tapson, Victor F.; Kaufman, John A.

doi:10.1016/j.jvir.2012.12.011

Cited by 26 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that if symptoms have been present for more than 10 days, in general, the complete thrombus resolution rate is reduced (10). It has also been reported in recent studies that the use of IVC filters in endovascular interventional operations reduces the risk of iatrogenic pulmonary embolism (10)(11)(12). In our study, IVC filters were successfully implanted in all patients, and no pulmonary embolism occurred in any of the patients.…”

Section: Discussionsupporting

confidence: 66%

Pharmacomechanical Thrombolytic Treatment in Symptomatic Acute and Subacute Deep Vein Thrombosis

et al. 2016

View full text Add to dashboard Cite

Background: In this study, we shared the implementation success and clinical results for 38 patients treated with the cleaner™ pharmacomechanical thrombectomy device. Objectives: The impact and results of pharmacomechanical thrombectomy treatment on patients with deep vein thrombosis in the symptomatic acute and subacute phases were assessed. Patients and Methods: Pharmacomechanical thrombectomy treatment was applied in a single session for 38 patients with lower extremity deep vein thrombosis in the acute and subacute phases between May 2012 and June 2014. Venography was performed and each assessment was made based on lysis rates and clinical results. Results: Deep vein thrombosis was found in the left lower extremity in 25 patients (65%) and in the right lower extremity in 13 patients (35%). No patient was found to have bilateral deep vein thrombosis. Thrombus localization was in the iliofemoral area in 17 patients (44%), the iliocaval area in three patients (8%), and the femoropopliteal area in 18 patients (56%). When thrombus resolution was assessed at the end of the process, grade III and grade II lysis was achieved in 36 (94%) out of 38 patients. Complete resolution was achieved in 28 patients (74%) in the acute and subacute groups. Conclusion: Pharmacomechanical thrombectomy provides very satisfactory results in a single procedure, as a new method in the treatment of acute and subacute deep vein thrombosis.

show abstract

Section: Discussionsupporting

confidence: 66%

Pharmacomechanical Thrombolytic Treatment in Symptomatic Acute and Subacute Deep Vein Thrombosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…One such filter, the Angel catheter (BiO 2 Medical, San Antonio, TX) can also serve as a central venous line and is currently on trial in the United States. 12…”

Section: Filter Designmentioning

confidence: 99%

“…The device is intended for short-term use and must be removed prior to discharge (the highest risk of PE in this patient population is within the first 10 days of ICU admission). 12 Data from the U.S. pivotal trial of more than 150 patients at 20 sites has been submitted for publication.…”

Section: Future Developmentsmentioning

confidence: 99%

Inferior Vena Cava Filters: When to Place and When to Remove

Moriarty

Steinberger

2017

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Pulmonary embolism (PE) is a common and feared result of deep vein thrombosis. While anticoagulation is the mainstay of management, interruption of flow of thrombus from leg veins to the pulmonary circulation is frequently desired either in lieu of or in addition to anticoagulation. Inferior vena cava filters have become frequently used to prevent PE despite a paucity of evidence for efficacy and increasing concerns about the long-term complications of indwelling filters.

show abstract

“…Outcomes of the Angel Catheter were initially reported from a pilot study of eight patients. 43 The combined filter and central venous catheters were all placed at the bedside without the use of fluoroscopy. There was a mean dwell time of 4 days and patients were followed up for 30 days following placement.…”

Section: Future Directionsmentioning

confidence: 99%

A Critical Review of Available Retrievable Inferior Vena Cava Filters and Future Directions

Montgomery

Kaufman

2016

Semin intervent Radiol

Self Cite

View full text Add to dashboard Cite

Inferior vena cava filters have been placed in patients for decades for protection against pulmonary embolism. The widespread use of filters has dramatically increased owing at least in part to the approval of retrievable vena cava filters. Retrievable filters have the potential to protect against pulmonary embolism and then be retrieved once no longer needed to avoid potential long-term complications. There are several retrievable vena cava filters available for use. This article discusses the different filter designs as well as the published data on these available filters. When selecting a filter for use, it is important to consider the potential short-term complications and the filters' window for retrieval. Understanding potential long-term complications is also critical, as these devices are approved for permanent placement and many filters are not retrieved. Finally, this article will address research into new designs that may be the future of vena cava filtration.

show abstract

Pilot Study Evaluating the Safety of a Combined Central Venous Catheter and Inferior Vena Cava Filter in Critically Ill Patients at High Risk of Pulmonary Embolism

Cited by 26 publications

References 12 publications

Pharmacomechanical Thrombolytic Treatment in Symptomatic Acute and Subacute Deep Vein Thrombosis

Pharmacomechanical Thrombolytic Treatment in Symptomatic Acute and Subacute Deep Vein Thrombosis

Inferior Vena Cava Filters: When to Place and When to Remove

A Critical Review of Available Retrievable Inferior Vena Cava Filters and Future Directions

Contact Info

Product

Resources

About